Evidence map›Paper›PMID 40869085›Full record

ReviewInternational journal of molecular sciences2025

Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation.

Tomasz Kowalczyk, Marek Staszewski, Magdalena Markowicz-Piasecka, Joanna Sikora, Catarina Amaro, Laurent Picot, Przemysław Sitarek

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomasz KowalczykDepartment of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.ORCID 0000-0002-4559-5015
Marek StaszewskiDepartment of Synthesis and Technology of Drugs, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0003-2783-522X
Magdalena Markowicz-PiaseckaDepartment of Applied Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0002-1012-6550
Joanna SikoraDepartment of Bioinorganic Chemistry, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0001-7044-9696
Catarina AmaroStudents Research Group (Erasmus Student), Department of Medical Biology, Medical University of Lodz, 90-151 Lodz, Poland.
Laurent PicotLittoral Environnement et Sociétés UMRi CNRS 7266 LIENSs, La Rochelle Université, 17042 La Rochelle, France.ORCID 0000-0003-4656-3557
Przemysław SitarekDepartment of Medical Biology, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0001-5495-3550

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bryostatin 1, a natural macrolide isolated from

Indexed as

Antineoplastic AgentsBryostatinsNeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationClinical Trials as TopicHumansProtein Kinase CAntineoplastic Agentsbryostatin 1BryostatinsProtein Kinase Canticancer effectBryostatin 1Bugula neritinaclinical trialsmodulator of protein kinase C

Identifiers

PMID40869085
PMCPMC12386199

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.